More news, no ads
SINCE 1819
SINCE 1819
Home Business Article
Cambridge Clinical Laboratories (CCL) is now offering a fingerprick blood test that indicates whether an individual has an increased risk of lung cancer and on average detects the disease four years before standard care.
The Oncimmune EarlyCDT Lung test is aimed at those worried about lung cancer, those whose family members have had it and those who have been exposed to environmental factors that may increase risk, such as smoking.
In a large NHS trial, the test has been shown to reduce late-stage lung cancer presentation by 36 per cent.
Dr Anthony Cooke, CEO of the Milton-based independent lab, said: “2020 threw a huge curveball for the world in the form of the Covid-19 pandemic. As a result, cancer healthcare has been hugely impacted.
“The new tests we are launching will help to ease the pressure of the NHS and support patients to take more of a lead with their healthcare. CCL wants to help; we know our tests will improve the lives of many.”
CLL points out that NHS waiting times for cancer referral and treatment are at a record high, and 80 per cent of lung cancer cases are diagnosed in the later stages with their healthcare. CCL wants to help; we know our tests will improve the lives of many.”
Lung cancer is one of the most common and serious types of cancer. About 48,500 people are diagnosed with it in the UK each year. More than eight out of 10 cases are caused by smoking.
To arrange a test, contact CCL via camclinlabs.co.uk.